Clinical Trials

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

105 enrolled

Phase 3 Active not recruiting

EGFR-mutant Non-small Cell Lung Cancer

NCT03784014 2025-12-11

MULTISARC

603 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT05642572 2025-12-05

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Phase 2 Recruiting

66 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05110196 2025-12-03

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Phase 4 Completed

50 enrolled

LymphoidOther hematologic neoplasm

Bronchial Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

825 enrolled

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT04926831 2025-10-16

Geometry-N

4 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04575025 2025-09-15

Special Drug Use-results Surveillance of Tabrecta Tablets

Completed

109 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04677595 2025-06-24

GeoMETry-C

37 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05243641 2025-06-11

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

Phase 1/2 Terminated

10 enrolled 11 charts

Breast

Breast Neoplasms

NCT04427072 2025-05-16

GeoMETry-III

Phase 3 Terminated

22 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT05703516 2025-01-14

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Recruiting

250 enrolled

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04139317 2024-10-09

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

76 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT04323436 2024-10-09

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

31 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT03484923 2024-06-18

PLATforM

196 enrolled 22 charts

Dermatologic

Melanoma

NCT05567055 2024-06-17

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05435846 2024-06-11

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

Phase 1 Terminated

3 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

373 enrolled 34 charts 3 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02159066 2024-03-05

LOGIC-2

158 enrolled 40 charts

Dermatologic

Melanoma

NCT02386826 2023-09-21

INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

CNSGastrointestinalGenitourinarySarcoma

65 enrolled

Carcinoma, Renal Cell, Glioblastoma, Colorectal Neoplasms, Gliosarcoma

NCT02795429 2023-07-03

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Phase 1/2 Completed

89 enrolled 37 charts

Gastrointestinal

Liver Neoplasms

NCT02335944 2023-06-18

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Phase 1/2 Terminated

177 enrolled 48 charts

Carcinoma, Non-Small-Cell Lung

NCT02019693 2023-03-21

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

20 enrolled 14 charts

Genitourinary

Kidney Neoplasms

NCT05675683 2023-01-09

Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib

Completed

68 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02750215 2022-03-14

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

20 enrolled 19 charts

Malignant Non-small Cell Neoplasm of Lung Stage IV

NCT02323126 2022-02-28

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

64 enrolled 28 charts

Carcinoma, Non-Small-Cell Lung

NCT03647488 2022-01-24

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

18 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT01911507 2021-10-13

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

35 enrolled

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01546428 2020-12-19

A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors

44 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT02474537 2020-12-10

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

31 enrolled

Hepatic Impairment

NCT02520752 2020-12-10

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

37 enrolled

Other solid neoplasm

cMET-dysregulated Advanced Solid Tumors

NCT02626234 2020-12-10

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

32 enrolled

Other solid neoplasm

cMET-dysregulated Advanced Solid Tumors

NCT04460729 2020-12-03

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Phase 2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02587650 2020-01-27

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

GastrointestinalHead & Neck

1 enrolled 7 charts

Dermatologic

Noonan Syndrome 6, Melanoma

NCT02205398 2019-01-22

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Phase 1 Terminated

13 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT03693339 2018-10-03

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Phase 2 Unknown

27 enrolled

Tumor-Agnostic

Neoplasms

NCT01870726 2018-05-30

Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma

Phase 1/2 Terminated

43 enrolled 22 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01072266 2017-11-22

A Dose-escalation Study in Subjects With Advanced Malignancies